A MULTI-CENTRE, OPEN-LABEL PHASE 2 TRIAL OF THE COMBINATION OF VB10.16 AND ATEZOLIZUMAB IN PATIENTS WITH ADVANCED OR RECURRENT, NON-RESECTABLE HPV16 POSITIVE CERVICAL CANCER - Vaccibody.com
2482
portfolio_page-template-default,single,single-portfolio_page,postid-2482,bridge-core-2.4.3,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-22.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.3.0,vc_responsive

A MULTI-CENTRE, OPEN-LABEL PHASE 2 TRIAL OF THE COMBINATION OF VB10.16 AND ATEZOLIZUMAB IN PATIENTS WITH ADVANCED OR RECURRENT, NON-RESECTABLE HPV16 POSITIVE CERVICAL CANCER